Objective: We apply three discrimination measures to evaluate the incremental value of biomarkers -above and beyond self-reported measures -for predicting all-cause mortality and assess whether all three lead to the same conclusions.
INTRODUCTION
Epidemiologists and clinicians have a long-standing interest in identifying biomarkers that have prognostic value in predicting health events or death. Here we broaden this conventional inquiry by examining the incremental value of an extensive set of biomarkersboth standard and non-clinical markers -in predicting survival, above and beyond questionnairebased information on self-reports of health and socio-demographic information. Since the 1990s, an increasing number of population-based social surveys have collected biological measures alongside detailed household questionnaires that obtain information on health and disability. Unfortunately, evaluations of the usefulness of these data collection efforts are seriously lacking, a critical concern in light of the financial costs, logistic complications, respondent burden, ethical concerns and threats to privacy of the data.
Determining the incremental value of biomarkers for risk assessment is not straightforward. In particular, statistical significance is insufficient because it is strongly influenced by sample size and because it fails to capture substantive importance. For such evaluations, epidemiologists and clinicians have relied primarily on measures of discriminationthat is, determining how well a regression model distinguishes individuals who experience an event from those who do not. The measure used most frequently is the area under the receiveroperating-characteristic curve (AUC). Because the focus of research has generally been on the incremental value of biomarkers, the corresponding metric has been the change in AUC (∆AUC) attributable to the biomarker(s) of interest.
A serious limitation of ∆AUC -its strong dependence on the strength of the baseline model -has resulted in very small improvements in the AUC when a marker has been added to a baseline model that discriminates very well (e.g., AUC > 0.80). In response to this limitation, alternative methods have been proposed to compare predictive risk models. What remains unclear is the extent to which different measures yield similar conclusions. Pencina and colleagues underscore the distinct strengths and weaknesses of various discrimination measures and argue for presentation of multiple measures when assessing the incremental predictive value of novel markers [1] . Steyerberg and colleagues demonstrate that different discrimination measures favor the inclusion of different marker [2] . Such recommendations and findings are disturbing because there are no guidelines for identifying the preferred metric: these discrimination measures do not have any clinical interpretation or clinically-based cutoff values [3] and consensus for quantifying improvements in risk prediction appears to be lacking [4] . In addition, how the measures rank various models is likely to depend on the particular research question.
In this paper we apply three discrimination measures to evaluate the prognostic value of a set of biomarkers that were collected in the Social Environment and Biomarkers of Aging Study (SEBAS) in Taiwan [5] , a pioneering survey of older adults. Similar arrays of markers have been included in other recent biosocial surveys. We consider four questions related to the value of adding biomarkers to models predicting five-year survival. First, do biomarkers have incremental value after adjusting for extensive self-reported information? Second, do changes in biomarker values provide better discrimination than a one-time measurement? Third, which cluster of biomarkers -standard cardiovascular/metabolic, inflammatory, or neuroendocrineprovides the strongest prediction? Finally, we pose a more nuanced question: which individual biomarkers are the strongest predictors?
An analysis of similar questions based only on the AUC was recently published [6] . Our objective is to assess the extent to which two additional discrimination measures provide consistent answers to these important issues.
METHODS

Data
Our data come from a cohort study in Taiwan, a population whose life expectancy and cause of death structure are similar to those observed in other industrialized countries including the US [7] [8] [9] . The SEBAS cohort was based on a nationally representative random sample of Taiwanese aged 54 and older in 2000. In 2000, in-home interviews were completed with 1,497 respondents, 1,023 of whom also completed a physical examination. Exam participants did not differ significantly from nonparticipants in ways likely to introduce serious bias [10] . Six years later, a follow-up was conducted with those who completed the 2000 exam and survived to 2006: Of the 846 who survived, 757 completed the in-home interview and 639 participated in the physical examination. The study protocol was approved by human subjects committees in Taiwan, Georgetown University and Princeton University. A public use dataset is available at http://www.icpsr.umich.edu/icpsrweb/NACDA/studies/3792/version/7.
The physical examination followed a similar protocol in both waves. Several weeks after the household interview, participants collected a 12-hour overnight urine sample (7pm to 7am), fasted overnight, and visited a nearby hospital the following morning for a physical examination. Union Clinical Laboratories in Taipei analyzed the blood and urine specimens; a sample of duplicate specimens was sent to Quest Diagnostics in the US for comparison. Details regarding response rates, sample attrition, exam participation, intra-lab reliability, inter-lab correlations, and compliance with the medical protocol are provided elsewhere [11] .
Survival status as of January 1, 2012 was ascertained by linkage to the death certificate file maintained by the Taiwan Department of Health and to the household registration database maintained by the Ministry of the Interior. The analysis sample was based on the longitudinal cohort that completed the exam in both 2000 and 2006 (n=639, 104 of whom died by December 31, 2011). The mean length of mortality follow-up was 5.1 years. Because 89 of the respondents had missing data for at least one covariate, we followed standard practices of multiple imputation [12, 13] based on five imputed datasets to handle missing data.
Biomarkers and Control Variables
Biomarkers. We include 19 biomarkers that have been shown by prior studies to be associated with all-cause mortality. They comprise three clusters of biologically-related markers: 1) eight standard cardiovascular/metabolic risk factors-systolic and diastolic blood pressure, high-density lipoprotein cholesterol (HDL), ratio of total to HDL cholesterol, triglycerides, glycoslyated hemoglobin, body mass index, and waist circumference; 2) four inflammatory markers-interleukin-6 (IL-6), high-sensitivity C-reactive protein (CRP), soluble intercellular adhesion molecule 1 (sICAM-1), and soluble E-selectin; and 3) four neuroendocrine markers-dehydroepiandrosterone sulfate (DHEAS), cortisol, epinephrine, and norepinephrine. We also include three markers that do not represent a common biological subsystem-creatinine clearance, albumin, and homocysteine.
Self-reported health indicators. Based on self-reports from 2006, we include six health indicators: 1) global self-assessed health ("Regarding your current state of health, do you feel it is excellent, good, average, not so good, or poor?"); 2) an index of mobility limitations; 3) whether the respondent was ever diagnosed with diabetes; 4) history of cancer; 5) number of hospitalizations in the past 12 months; and 6) smoking status (never, former, current). The mobility index is based on self-reported difficulty performing each of eight physical tasks without assistance and is calculated according to the method described in Long and Pavalko [14] .
Social and demographic characteristics. We control for key demographic and social characteristics that are known to be important predictors of mortality. Demographic variables comprise age, sex, urban residence, and ethnicity (Mainlander vs. Taiwanese). Social measures comprise educational attainment (in years), social integration, and perceived social support. An index of social integration is based on 10 indicators and is constructed following the strategy of Cornwell and Waite [15] . An index of perceived social support is based on four questions pertaining to potential instrumental and emotional support from family and friends. Additional details are provided in Table 1 .
Measures of Discrimination
Area under the receiver operating characteristic curve (AUC). The most common approach for quantifying the predictive power of a model is the C-statistic or AUC. The receiveroperating-characteristic curve is a plot of true positive rates (sensitivity) against false positive rates (1-specificity) for all possible cutoff values that discriminate between two groups (e.g., those who died vs. those who survived). The AUC can be interpreted as the probability that the model predicts a higher probability of death for those who died than for those who survived [16] . An AUC of 0.5 indicates that the model performs no better than chance, whereas an AUC of 1.0 represents perfect accuracy.
For the purposes of evaluating the incremental value of a marker, the AUC has drawbacks. In particular, ∆AUC is insensitive to the inclusion of a novel biomarker if the baseline model possesses good discrimination, even if the effect size is large. Furthermore, ΔAUC ignores the magnitude of the difference in probabilities between models [17] ; it considers the rank order of cases and noncases rather than the actual predicted probabilities [18] . In an effort to address criticisms of the AUC, researchers have developed alternative measures of discrimination based on reclassification methods.
Net Reclassification Improvement (NRI).
The purpose of reclassification is to determine the extent to which inclusion of markers in a risk model improves the classification of individuals into clinically meaningful risk strata [18, 19] . The Net Reclassification Improvement (NRI) uses reclassification tables constructed separately for individuals that experience the event and those that do not [20] . It then quantifies the correct movement between risk categories (i.e., upwards for those with the event and downwards for those without the event). One drawback of the NRI is that it requires meaningful risk categories a priori, and the results are sensitive to the choice of categories [19, 20] . A newer category-free version, NRI(>0), addresses this issue by redefining movement based on changes in the predicted probabilities: upward for decedents and downward for survivors [21] . One can think of the NRI(>0) as a limiting case of the categorybased NRI where each unique predicted probability represents its own category [1] . The NRI(>0) represents a summary measure of the correct upward versus downward movement in model-based probabilities for events and non-events [1] .
The NRI(>0) is calculated as:
where New, Event and Old, Event represent the predicted probability of the event among those who experienced the event based on the "new" and "old" models, respectively; New, Non-Event and Old, Non-Event denote the corresponding probabilities among those who did not experience the event. (Up|Event) represents the probability that New, Event is greater than Old, Event , while �Up�Non-Event� is the corresponding quantity among those without the event. Thus, the NRI(>0) is the difference between the probability of upward movement for the two groups multiplied by two.
Among the discrimination measures discussed here, Pencina et al. [1] argue that the NRI(>0) is the best indicator of the true discriminatory potential of the added marker; unlike the AUC, the NRI depends mainly on the effect size of the added predictor rather than the strength of the baseline model. Thus, it addresses one of the major criticisms of the AUC, but it still does not take into account the magnitude of movements: it focuses only on net numbers with altered risk [1] . Consequently, as Cook shows, one can obtain anomalous results; for example, a new model may seem inferior because of an increased number of changes in the wrong direction, even though the incorrect changes are smaller than the correct changes [22] . Pencina et al. point out that, if there is some minimum change in risk considered to be clinically meaningful, it may be preferable to calculate NRI(>x), where x represents that minimal change [1] .
Integrated Discrimination Improvement (IDI).
Unlike the AUC and NRI, the IDI incorporates information about the magnitudes of changes in probabilities by weighting the movements by their magnitudes. The IDI is based on the difference in discrimination slopes of models with and without the new markers [20] , where the discrimination slope is defined as the absolute difference in the average prediction between those who experienced the event and those who did not [23] . Thus, the IDI is calculated as:
where � New, Event and � New, Non-Event represent the mean predicted probabilities of an event based on the "new" model for those who had the event and those who did not, respectively; � Old, Event and � Old, Non-Event denote the corresponding means based on the "old" model. The IDI can be directly interpreted as the amount of increase in the difference between the mean predicted probability of events and non-events [1] .
Like ΔAUC, the IDI also represents a measure of overall improvement in sensitivity and specificity, but whereas the AUC weights cutoffs associated with high sensitivity more heavily, the IDI assigns equal weight to all values of sensitivity [20] . The mean probability of an event among those who experienced the event ( � Event ) represents the average sensitivity, whereas the Slope (Old Model) Slope (New Model) mean probability of an event among those who did not experience the event (� Non-Event ) can be viewed as the average of 1-specificity. Thus, rewriting Equation (2) as:
we see that the IDI can be interpreted as the difference between improvement in average sensitivity and any potential increase in the average of 1-specificity.
The IDI bridges the perspectives of the ΔAUC, which depends heavily on the strength of the baseline model, and NRI(>0), which is the least dependent on the baseline model strength [1] . Whether such dependence is desirable is debatable. Kerr et al. argue that invariance to the strength of the baseline model is not necessarily advantageous: if the baseline model is almost perfect, then the incremental value of any additional marker should be small [3] . Pencina et al. contend that the preferred metric depends on the purpose: the AUC is preferred when the focus is on the model itself rather than the variables to be added, whereas the NRI(>0) is better for assessing the true discriminatory potential of a new marker compared with other markers [1, 24] . The IDI falls somewhere in between.
The IDI differs from the AUC and the NRI(>0) in two additional ways. First, the IDI takes into account the magnitude of changes in the probabilities, whereas the AUC and NRI(>0) are based only on the net numbers with altered risk. Second, the IDI depends on the event rate in a way that the other measures do not. Thus, it is more heavily influenced by model calibration (i.e., the ability to correctly estimate the probability of an event) and cannot be compared across studies with different event rates.
Analytic Strategy
Descriptive statistics (Tables 1 and 2 ) are weighted to account for the sampling design and for differential response rates by various covariates. Using unweighted data, we estimate a series of Gompertz hazard models, with time measured in terms of age. Because initial tests revealed evidence of non-proportional hazards (i.e., the effect varies by age) for several covariates -perceived social support, current smoker, and the change (2000-06) in DHEAS -we include interactions between these variables and age.
In order to compare effect sizes across predictors, we standardize (mean=0, standard deviation=1) all continuous measures prior to model fitting. We transform biomarkers with a skewed distribution using a logarithm or power transformation (see Table 2 ) to better approximate normality, which substantially improves the model fit.
To address the questions presented above, we examine the improvement in discrimination -assessed by ∆AUC, NRI(>0), and IDI -based on a comparison of models with and without the set of indicators being evaluated. We use the coefficients from each model to compute the predicted probability of dying by the end of follow-up for each respondent. The discrimination measures are calculated from the predicted probabilities and the observed binary outcome (death vs. survival); see cph.georgetown.edu/ms410s.pdf for details. All analyses are performed using Stata 12.1 (StataCorp, College Station, TX) [25] . To compute the AUC, we use Stata's "roctab" and "roccomp" procedures.
Change in Sensitivity
Change in (1-Specificity) Table 3 shows comparisons among selected models in terms of the three discrimination measures. Although there are no established benchmarks, Pencina and colleagues suggest ∆AUC>0.01 represents a meaningful improvement, while NRI(>0) greater than 0.6 indicates a strong contribution and NRI(>0) between 0.2 and 0.6 implies moderate improvement [1, 20] . In the results below, we use these somewhat arbitrary values as benchmarks. Researchers do not provide a corresponding gauge for IDI. However, IDI values can be interpreted as the increase in average sensitivity (given fixed specificity).
RESULTS
Do biomarkers retain incremental prognostic value beyond self-reports?
A comparison of Models 1 and 2 suggests that biomarkers (measured in 2006) yield substantial incremental value in predicting mortality for the period 2006-11 beyond that of selfreported health variables: ∆AUC= 0.04, NRI(>0)=0.74, and IDI=0.09.
Do changes in biomarkers yield better discrimination than one-time measurement?
A comparison of Models 2 and 3 reveals that the addition of the earlier biomarkers (2000) -i.e., incorporating change in biomarker values -yields moderate improvement: ∆AUC=0.02, NRI(>0)=0.56, and IDI=0.07.
Which cluster of biomarkers is the strongest predictor?
We evaluate the contributions of eight cardiovascular/metabolic markers (Model 4a), four inflammatory markers (Model 4b), and four neuroendocrine markers (Model 4c) by comparing each with Model 1. All three discrimination measures suggest that inflammatory markers yield more predictive power than cardiovascular/metabolic or neuroendocrine markers.
Which individual biomarkers are the strongest predictors?
Using Model 1 as the baseline, we assess the contribution of each biomarker by adding the 2006 level and 2000-06 change for that marker. Figure 1 shows the top 10 biomarkers ranked by ∆AUC, NRI(>0), and IDI.
For each discrimination measure, IL-6 is the strongest predictor and all four inflammatory markers make the top 10; sICAM-1 consistently has a high ranking as well. Although CRP is the only one of these markers used clinically, it ranks lowest of the four inflammatory markers according to all three measures.
The cardiovascular/metabolic markers in the top 10 generally rank near the bottom, and none ranks in the top 10 by all discrimination measures. Systolic blood pressure achieves a rank within the top 10 on two discrimination measures; other cardiovascular/metabolic markers appear in the top 10 only for ΔAUC (glycosylated hemoglobin) or IDI (HDL, body mass index, ratio total cholesterol to HDL).
DHEAS is the only neuroendocrine marker on all three lists. Epinephrine has a top 10 ranking for two of these, whereas norepinephrine and cortisol appear on the list for only one discrimination measure.
Among the three other unrelated markers, homocysteine ranks second or third on each list. Creatinine clearance attains the top 10 ranking for two discrimination measures, although it fails to rank higher than 8 th . Serum albumin never appears in the top 10.
When we evaluate the contribution of each biomarker relative to the discrimination benchmarks described above, we find that four biomarkers yield a meaningful improvement in ΔAUC (>0.01): IL-6, DHEAS, homocysteine, and sICAM-1. One of these, IL-6, makes a strong contribution based on the NRI(>0); another six (homocysteine, sICAM-1, soluble Eselectin, DHEAS, systolic blood pressure, and CRP) yield a moderate improvement. These seven biomarkers also produce a greater than 1% improvement in sensitivity based on the IDI.
When we examine the robustness of our findings by excluding 34 respondents with CRP > 10 mg/L (indicative of acute infection), we find most of the results unchanged. In particular, the four inflammatory markers remain among the top 10 by all criteria, although they decline in rank, while homocysteine now ranks first. Three markers (homocysteine, DHEAS, and IL-6) continue to satisfy ΔAUC >0.01, and the seven markers that produce at least a moderate improvement in the NRI(>0) remain the same.
DISCUSSION
Ascertaining whether particular biomarkers enhance prediction of downstream health or mortality above and beyond conventional factors has been a contentious issue. Although there are numerous statistical criteria that need to be satisfied at an early stage of analysis (for example, statistical significance of the markers and adequate model calibration), researchers tend to focus ultimately on discrimination: does the marker improve our ability to distinguish between those who experience the event and those who do not? The merits of alternative measures of discrimination have been frequently debated, but as yet, there is no consensus about which measure is "best." Despite a large literature on evaluating novel markers, surprisingly few studies have attempted to assess the consistency of findings based on different measures of discrimination.
In this paper, we evaluate the robustness of conclusions about the utility of a set of biomarkers for predicting five-year survival in a general older population based on three frequently used discrimination measures. Several broad conclusions are consistent across the ∆AUC, NRI(>0), and IDI: (1) inclusion of biomarkers substantially enhances five-year survival prediction from a baseline model that incorporates numerous self-reported indicators of health; (2) inclusion of information on changes in biomarkers over the preceding six-year period yields a moderate improvement over one-time measurement; and (3) when considered as clusters, inflammatory markers offer stronger prediction than either cardiovascular/metabolic or neuroendocrine measures.
When we address a more specific question -which biomarkers are the strongest predictors -the findings are more nuanced. Still, there is considerable overlap in results: all three discrimination measures underscore the utility of inflammatory markers and homocysteine levels. Surprisingly, standard clinical markers that reflect lipids, obesity, and blood pressure generally have relatively low prognostic power.
At the same time, differences are apparent. For example, ∆AUC and to a lesser extent NRI(>0) favor the inclusion of neuroendocrine over cardiovascular/metabolic markers (despite only half as many variables in the former category), whereas IDI favors the cardiovascular/metabolic markers. We see this difference despite the fact that none of the discrimination measures penalizes for the number of parameters. The inconsistency stems in part from the fact that ΔAUC disproportionately weights high levels of sensitivity, where neuroendocrine markers outperform cardiovascular/metabolic factors. At lower levels of sensitivity, the cardiovascular/metabolic factors generally perform better than the neuroendocrine markers. The rank ordering of the 10 most predictive biomarkers also varies across discrimination measures.
One important limitation of this analysis is that the benchmarks we use for the discrimination measures were originally intended for testing a single marker, rather than many markers. This distinction is important. For example, if an NRI(>0) of 0.60 is indicative of a strong contribution for one marker, what magnitude should be used for 19 markers? In principle, we could impose a penalty for the number of parameters added to the model. In addition, because previous research demonstrates that ∆AUC depends on the strength of the baseline model [1] , we could permit the benchmark to vary accordingly, although there is little guidance on how to do so.
It is important to bear in mind that this study has not considered health outcomes beyond mortality or the many other uses of biomarkers within population-based household surveys. The value of including biomarkers undoubtedly varies across research objectives. Moreover, the cost, complex logistics and additional burden posed by the inclusion of biomarkers in large surveys of the general population must be borne in mind. Still, at least from the point of view of predicting mortality -a well-measured outcome highly correlated with myriad health measuresthese findings provide strong support for biomarker collection within household surveys and moderate support for longitudinal collection of such markers -particularly with respect to inflammatory markers.
On the one hand, the consistency of most of these results across the three discrimination measures should provide some comfort to researchers. On the other hand, our findings should not signal that future evaluations based on multiple discrimination measures are superfluous. As we have shown, the degree of consistency across metrics varies with the level of detail inherent in the research question. Researchers would be wise to confirm findings with multiple metrics, for example, considering ∆AUC >0.01 as a necessary but not sufficient benchmark, and using the NRI(>0) and the IDI as robustness checks. If all three discrimination measures yield similar conclusions, the utility of the biomarker is on much firmer ground than if the metrics produce disparate results.
Upon discovering that most published research findings are inaccurate and that many of the associations reported in highly cited biomarker studies are exaggerated, Ioannidis and colleagues argue that "the standards for claiming success should be higher" [26, 27] . This analysis provides one small step in the right direction.
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